NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESSWIRE / July 22, 2022 / XPhyto Therapeutics Corp. ("XPhyto" or the "Company") (CSE:XPHY) is pleased to announce a non-brokered private placement for gross proceeds of a maximum of CAD$3,600,000 (the "Offering") of units (the "Units") at an issue price of $0.36 per Unit. Each Unit will consist of one common share in the capital of the Company (a "Common Share") and one half of one Common Share purchase Warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to acquire one Common Share (a "Warrant Share") at an exercise price of $0.50 per Warrant Share for a period of 24 months from the date of issuance. The Offering is anticipated to result in a maximum of 10,000,000 Units of the Company being issued, and the Offering may close in one or more tranches.
The Company intends to use the proceeds from the Offering to fund its research, development, and commercialization activities and for general working capital purposes.
All securities issued or issuable in connection with closing of the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. Finder's fees will be paid in connection with the Offering pursuant to applicable CSE policies and Canadian securities regulations.
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Email: info@xphyto.com
Phone: +1 780-818-6422